Literature DB >> 28153657

Fertility treatments and pediatric neoplasms of the offspring: results of a population-based cohort with a median follow-up of 10 years.

Tamar Wainstock1, Asnat Walfisch2, Ilana Shoham-Vardi3, Idit Segal4, Avi Harlev5, Ruslan Sergienko3, Daniella Landau6, Eyal Sheiner2.   

Abstract

OBJECTIVE: Studies have questioned the long-term health effects of offspring conceived after fertility treatments.
METHODS: We aimed to evaluate whether an association exists between mode of conception (in vitro fertilization, ovulation induction, or spontaneous pregnancy) and neoplasm risk (both benign and malignant tumors) among the offspring; we observed the offspring for up to 18 years. STUDY
DESIGN: A population-based cohort analysis was performed that compared the risk for neoplasms among children (up to the age of 18 years) based on mode of conception. Neoplasm diagnoses were based on hospital records of the same single tertiary center in the region. All singletons born during from 1991-2013 and discharged alive were included in the study. Offspring with congenital malformations were excluded from the analysis. Kaplan-Meier survival curves were constructed to compare cumulative neoplasms incidence; multivariable survival analyses were used to control for confounders that included gestational age, pregnancy complications, and maternal factors.
RESULTS: During the study period, 242,187 newborn infants met the inclusion criteria: 2603 (1.1%) were conceived after in vitro fertilization; 1721 (0.7%) were conceived after ovulation induction treatments, and 237,863 (98.3%) were conceived spontaneously. During the follow-up period (median, 10.55 years), 1498 neoplasms(0.6%) were diagnosed. Incidence density rate for neoplasms was higher among children conceived either after in vitro fertilization (1.5/1000 person years) or ovulation induction treatments (1.0/1000 person years), as compared with naturally conceived children (0.59/1000 person years; Kaplan-Meier log rank, P<.001). The association between in vitro fertilization and total pediatric neoplasms and the association between any fertility treatments and malignancies remained significant; we controlled for confounders such as gestational diabetes mellitus, hypertensive disorders, preterm birth, and maternal age (adjusted hazard ratio, 2.48; 95% confidence interval, 1.71-3.50; and adjusted hazard ratio, 1.96; 95% confidence interval, 1.14-3.36, for all neoplasms and all malignancies, respectively).
CONCLUSION: Children conceived after fertility treatments are at an increased risk for pediatric neoplasms.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  assisted reproduction technology; childhood cancer; fertility treatment; in vitro fertilization; ovulation induction

Mesh:

Year:  2017        PMID: 28153657     DOI: 10.1016/j.ajog.2017.01.015

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  11 in total

1.  Prenatal Exposure to Preeclampsia and Long-Term Ophthalmic Morbidity of the Offspring.

Authors:  Eliel Kedar Sade; Tamar Wainstock; Erez Tsumi; Eyal Sheiner
Journal:  J Clin Med       Date:  2020-04-28       Impact factor: 4.241

2.  Advanced maternal age during pregnancy and the risk for malignant morbidity in the childhood.

Authors:  Majdi Imterat; Tamar Wainstock; Eyal Sheiner; Joseph Kapelushnik; Laura Fischer; Asnat Walfisch
Journal:  Eur J Pediatr       Date:  2018-04-08       Impact factor: 3.183

3.  Assisted reproductive technologies (ART) and childhood cancer: is the risk real?

Authors:  Paolo Emanuele Levi-Setti; Pasquale Patrizio
Journal:  J Assist Reprod Genet       Date:  2018-07-24       Impact factor: 3.412

4.  Preconception nutraceutical food supplementation can prevent oxidative and epigenetic DNA alterations induced by ovarian stimulation for IVF and increases pregnancy rates.

Authors:  W Decleer; F Comhaire; K De Clerck; W Vanden Berghe; G Devriendt; K Osmanagaoglu
Journal:  Facts Views Vis Obgyn       Date:  2020-05-07

5.  A call for more responsible use of Assisted Reproductive Technologies (ARTs) in male infertility: the hidden consequences of abuse, lack of andrological investigation and inaction.

Authors:  Jorge Hallak
Journal:  Transl Androl Urol       Date:  2017-10

Review 6.  Early Life Oxidative Stress and Long-Lasting Cardiovascular Effects on Offspring Conceived by Assisted Reproductive Technologies: A Review.

Authors:  Huixia Yang; Christina Kuhn; Thomas Kolben; Zhi Ma; Peng Lin; Sven Mahner; Udo Jeschke; Viktoria von Schönfeldt
Journal:  Int J Mol Sci       Date:  2020-07-22       Impact factor: 5.923

7.  Cancer risk among children conceived by fertility treatment.

Authors:  Tingting Wang; Lizhang Chen; Tubao Yang; Lesan Wang; Lijuan Zhao; Senmao Zhang; Ziwei Ye; Letao Chen; Zan Zheng; Jiabi Qin
Journal:  Int J Cancer       Date:  2019-01-03       Impact factor: 7.396

8.  Risk of cancer in children and young adults conceived by assisted reproductive technology.

Authors:  Mandy Spaan; Alexandra W van den Belt-Dusebout; Marry M van den Heuvel-Eibrink; Michael Hauptmann; Cornelis B Lambalk; Curt W Burger; Flora E van Leeuwen
Journal:  Hum Reprod       Date:  2019-04-01       Impact factor: 6.918

9.  The Use of Assisted Reproductive Technology by European Childhood Cancer Survivors.

Authors:  Anja Borgmann-Staudt; Simon Michael; Greta Sommerhaeuser; Marta-Julia Fernández-González; Lucía Alacán Friedrich; Stephanie Klco-Brosius; Tomas Kepak; Jarmila Kruseova; Gisela Michel; Anna Panasiuk; Sandrin Schmidt; Laura Lotz; Magdalena Balcerek
Journal:  Curr Oncol       Date:  2022-08-15       Impact factor: 3.109

10.  Melatonin and Caffeine Supplementation Used, Respectively, as Protective and Stimulating Agents in the Cryopreservation of Human Sperm Improves Survival, Viability, and Motility after Thawing compared to Traditional TEST-Yolk Buffer.

Authors:  Juliana R Pariz; Caroline Ranéa; Rosa A C Monteiro; Donald P Evenson; Joël R Drevet; Jorge Hallak
Journal:  Oxid Med Cell Longev       Date:  2019-10-23       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.